Cytek Biosciences, Inc.

As of October 31, 2025, Cytek Biosciences, Inc. is in a mildly bearish trend, with daily moving averages and weekly KST indicating bearish signals, despite some mildly bullish MACD readings, and the stock has underperformed the S&P 500 with a year-to-date return of -39.91%.

As of October 31, 2025, Cytek Biosciences, Inc. shows a mildly bearish trend with daily moving averages indicating bearish signals, while its year-to-date return is -39.91%, significantly underperforming the S&P 500's 16.30%.

As of October 24, 2025, Cytek Biosciences, Inc. exhibits a neutral technical trend with mixed signals, showing mildly bullish MACD and KST on weekly but bearish RSI and moving averages on daily, indicating a sideways market.

As of October 24, 2025, Cytek Biosciences, Inc. shows a neutral technical trend with mixed indicators, including a mildly bullish weekly MACD and bearish RSI, leading to conflicting signals overall.

As of October 24, 2025, Cytek Biosciences, Inc. shows a neutral technical trend with mixed signals, outperforming the S&P 500 recently but experiencing significant negative returns year-to-date and over the past year.

As of August 29, 2025, Cytek Biosciences, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness and a year-to-date return of -36.98%, significantly underperforming the S&P 500's 12.22%.

As of May 9, 2023, Cytek Biosciences, Inc. has shifted from an attractive to a risky valuation grade due to overvaluation indicated by poor financial metrics and significant underperformance relative to the S&P 500.

As of May 9, 2023, Cytek Biosciences, Inc. is considered overvalued with a valuation grade of risky, reflected by a Price to Book Value of 1.15, a negative ROCE of -20.58%, and a year-to-date stock return of -51.93%, significantly underperforming the S&P 500's 2.44% return.

As of June 13, 2025, Cytek Biosciences, Inc. is in a bearish trend with moderate strength, indicated by bearish daily moving averages, a bearish monthly MACD, and a mildly bearish weekly Bollinger Bands, while the RSI shows no momentum signals.

Cytek Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $41 million and a net loss of $11 million as of March 2025. The company has a market cap of $404.04 million and does not pay dividends.

As of Jun 18, Cytek Biosciences, Inc. has a market capitalization of 404.04 million, with net sales of 197.06 million and a net profit of -11.25 million over the latest four quarters. Shareholder's funds are reported at 395.74 million, and total assets amount to 502.08 million.